Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An update from Ondine Biomedical, Inc. ( (GB:OBI) ) is now available.
Ondine Biomedical Inc. announced that Non-executive Director Margaret Shaw has increased her stake in the company by purchasing 30,000 shares at 12 pence each. This move comes as the company continues recruiting for its Phase 3 clinical trials, reflecting internal confidence in its ongoing projects and potentially bolstering market confidence amidst regulatory advancements for its products.
More about Ondine Biomedical, Inc.
Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, known as photodisinfection. The company has a range of investigational products based on its proprietary technology, including a nasal photodisinfection system approved in Canada and Europe, and currently in clinical trials in the U.S. for various medical indications.
YTD Price Performance: 31.43%
Average Trading Volume: 528,037
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £48.48M
For an in-depth examination of OBI stock, go to TipRanks’ Stock Analysis page.
